Cardio-Protective of Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients With Type 2 Diabetes
Phase of Trial: Phase IV
Latest Information Update: 20 Dec 2018
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary) ; Dapagliflozin/saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 11 Dec 2018 Status changed from not yet recruiting to recruiting.
- 17 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 22 Oct 2018.
- 14 Sep 2018 New trial record